---
title: "Xintian Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 16.1809 million yuan, a year-on-year decrease of 73.47%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263461118.md"
description: "According to the Zhitong Finance APP, Xintian Pharma released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 559 million yuan, a year-on-year decrease of 15.47%. The net profit attributable to shareholders of the listed company was 16.1809 million yuan, a year-on-year decrease of 73.47%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 13.5545 million yuan, a year-on-year decrease of 67.93%"
datetime: "2025-10-30T08:43:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263461118.md)
  - [en](https://longbridge.com/en/news/263461118.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263461118.md)
---

# Xintian Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 16.1809 million yuan, a year-on-year decrease of 73.47%

According to the Zhitong Finance APP, Xintian Pharma (002873.SZ) released its third-quarter report for 2025. In the first three quarters, the company achieved an operating income of 559 million yuan, a year-on-year decrease of 15.47%. The net profit attributable to shareholders of the listed company was 16.1809 million yuan, a year-on-year decrease of 73.47%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 13.5545 million yuan, a year-on-year decrease of 67.93%

### Related Stocks

- [002873.CN](https://longbridge.com/en/quote/002873.CN.md)

## Related News & Research

- [16:51 ETBeverly Hills MD ProRetinol Age Rewind x3 Officially Launches: A New Era of Gentle, Slow-Released Retinol Skincare Backed by Plastic Surgeons](https://longbridge.com/en/news/286966075.md)
- [METiS TechBio presents late-breaking cardiomyocyte LNP delivery data at CRS meeting](https://longbridge.com/en/news/287051904.md)
- [09:35 ETOpen Medicine Launches Ahead of ASCO, Introducing "Living Algorithms" for Real-Time Oncology Decision-Making](https://longbridge.com/en/news/286923155.md)
- [Orkla’s OV UK Buys Phoenix Brands to Boost Sweet Ingredients Footprint](https://longbridge.com/en/news/286763926.md)
- [Lipocine Showcases Phase 3 Data for Postpartum Depression](https://longbridge.com/en/news/286923466.md)